These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
469 related articles for article (PubMed ID: 27336396)
21. High Posttransplant Cancer Incidence in Renal Transplanted Patients With Pretransplant Cancer. Hellström V; Lorant T; Döhler B; Tufveson G; Enblad G Transplantation; 2017 Jun; 101(6):1295-1302. PubMed ID: 27163539 [TBL] [Abstract][Full Text] [Related]
22. Impact of Pre-Transplant Malignancy on Outcomes After Kidney Transplantation: United Network for Organ Sharing Database Analysis. Livingston-Rosanoff D; Foley DP; Leverson G; Wilke LG J Am Coll Surg; 2019 Dec; 229(6):568-579. PubMed ID: 31666186 [TBL] [Abstract][Full Text] [Related]
23. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Cherikh WS; Kauffman HM; McBride MA; Maghirang J; Swinnen LJ; Hanto DW Transplantation; 2003 Nov; 76(9):1289-93. PubMed ID: 14627905 [TBL] [Abstract][Full Text] [Related]
24. Impact of pre-existing hepatitis B infection on the outcomes of kidney transplant recipients in the United States. Reddy PN; Sampaio MS; Kuo HT; Martin P; Bunnapradist S Clin J Am Soc Nephrol; 2011 Jun; 6(6):1481-7. PubMed ID: 21566110 [TBL] [Abstract][Full Text] [Related]
25. Association of Baseline Viral Serology and Sirolimus Regimens With Kidney Transplant Outcomes: A 14-Year Registry-Based Cohort Study in the United States. Santos AH; Casey MJ; Xuerong W; Womer KL Transplantation; 2017 Feb; 101(2):377-386. PubMed ID: 28121742 [TBL] [Abstract][Full Text] [Related]
26. Effects of antibody induction on transplant outcomes in human leukocyte antigen zero-mismatch deceased donor kidney recipients. Kuo HT; Huang E; Emami S; Pham PT; Wilkinson AH; Danovitch GM; Bunnapradist S Transplantation; 2012 Mar; 93(5):493-502. PubMed ID: 22306574 [TBL] [Abstract][Full Text] [Related]
27. Quantifying prognostic impact of prescription opioid use before kidney transplantation through linked registry and pharmaceutical claims data. Lentine KL; Yuan H; Tuttle-Newhall JE; Xiao H; Chawa V; Axelrod D; Brennan DC; Dharnidharka VR; Beuer C; Schnitzler MA Transplantation; 2015 Jan; 99(1):187-96. PubMed ID: 25531895 [TBL] [Abstract][Full Text] [Related]
28. Long-term Kidney Transplant Outcomes in Primary Glomerulonephritis: Analysis From the ERA-EDTA Registry. Pippias M; Stel VS; Aresté-Fosalba N; Couchoud C; Fernandez-Fresnedo G; Finne P; Heaf JG; Hoitsma A; De Meester J; Pálsson R; Ravani P; Segelmark M; Traynor JP; Reisæter AV; Caskey FJ; Jager KJ Transplantation; 2016 Sep; 100(9):1955-62. PubMed ID: 26588008 [TBL] [Abstract][Full Text] [Related]
29. Risk factors of long-term graft loss in renal transplant recipients with chronic allograft dysfunction. Khalkhali HR; Ghafari A; Hajizadeh E; Kazemnejad A Exp Clin Transplant; 2010 Dec; 8(4):277-82. PubMed ID: 21143092 [TBL] [Abstract][Full Text] [Related]
30. De Novo Malignant Neoplasms in Renal Transplant Patients. Yılmaz Akçay E; Tepeoğlu M; Özdemir BH; Deniz E; Börcek P; Haberal M Exp Clin Transplant; 2016 Nov; 14(Suppl 3):100-105. PubMed ID: 27805524 [TBL] [Abstract][Full Text] [Related]
31. Solid Organ Transplantation in Patients With Preexisting Malignancies in Remission: A Propensity Score Matched Cohort Study. Acuna SA; Sutradhar R; Kim SJ; Baxter NN Transplantation; 2018 Jul; 102(7):1156-1164. PubMed ID: 29557910 [TBL] [Abstract][Full Text] [Related]
32. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Caillard S; Dharnidharka V; Agodoa L; Bohen E; Abbott K Transplantation; 2005 Nov; 80(9):1233-43. PubMed ID: 16314791 [TBL] [Abstract][Full Text] [Related]
33. Practice patterns in arteriovenous fistula ligation among kidney transplant recipients in the United States Renal Data Systems. Hicks CW; Bae S; Pozo ME; DiBrito SR; Abularrage CJ; Segev DL; Garonzik-Wang J; Reifsnyder T J Vasc Surg; 2019 Sep; 70(3):842-852.e1. PubMed ID: 30853386 [TBL] [Abstract][Full Text] [Related]
35. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720 [TBL] [Abstract][Full Text] [Related]
36. Pretransplant malignancy in pediatrics is not a risk factor for renal graft failure. Mandel A; Robinson SG; Peticca B; Prudencio TM; Karhadkar SS Pediatr Transplant; 2024 Feb; 28(1):e14697. PubMed ID: 38317342 [TBL] [Abstract][Full Text] [Related]
37. CD20 antigen expression by lymphoproliferative disorders after kidney transplant is independently associated with a poor outcome: PTLD.Int survey. Khedmat H; Taheri S Exp Clin Transplant; 2012 Aug; 10(4):325-31. PubMed ID: 22758374 [TBL] [Abstract][Full Text] [Related]
38. The association of pretransplant HeartMate II left ventricular assist device placement and heart transplantation mortality. Donneyong M; Cheng A; Trivedi JR; Schumer E; McCants KC; Birks EJ; Slaughter MS ASAIO J; 2014; 60(3):294-9. PubMed ID: 24614355 [TBL] [Abstract][Full Text] [Related]
39. Heart allograft involvement by posttransplant lymphoproliferative disorders: report from the PTLD. Int survey. Khedmat H; Taheri S Exp Clin Transplant; 2011 Aug; 9(4):258-64. PubMed ID: 21819371 [TBL] [Abstract][Full Text] [Related]
40. Avoiding delays in time to renal transplantation: Pretransplant thyroid malignancy does not affect patient or graft survival after renal transplantation. Delman AM; Turner KM; Ammann AM; Tang A; Steward D; Holm TM Surgery; 2022 Jan; 171(1):220-226. PubMed ID: 34303544 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]